Ahamad Anesa, Stevens Craig W, Smythe W Roy, Liao Zhongxing, Vaporciyan Ara A, Rice David, Walsh Garrett, Guerrero Thomas, Chang Joe, Bell Brent, Komaki Ritsuko, Forster Kenneth M
Department of Radiation Oncology, Section of Thoracic Molecular Oncology, The University of Texas M. D. Anderson Cancer Center, Houston, Texas 77030, USA.
Cancer J. 2003 Nov-Dec;9(6):476-84. doi: 10.1097/00130404-200311000-00008.
Malignant pleural mesothelioma often recurs locally in spite of aggressive resection by extrapleural pneumonectomy and conventional radiotherapy. This may be due to failure to recognize the extent of clinical target volume (CTV) or suboptimal dose delivery to a target that abuts the heart, esophagus, liver, lung, kidney, and spinal cord. We report how these geometric/dosimetric constraints were overcome by exploiting intensity-modulated radiotherapy in the first cohort patient.
Twenty-eight patients who had undergone extrapleural pneumonectomy were treated with intensity-modulated radiotherapy. The CTV included the surgically violated inner chest wall, insertion of diaphragm, pleural reflections, and deep margin of the incision. CTV delineation was facilitated by intraoperative radio-opaque marking. Motion was assessed. CTV doses were 45-50 Gy with boosts taken to 60 Gy.
Despite the large, irregular CTV (median, 4151 cc; range, 2667-7286 cc), an average of 97% of the CTV was covered to the target dose (range, 92%-100%). Respiratory motion was minimal because of immobility of the prosthetic diaphragm. Normal tissue dose constraints were met. The commonest effects were nausea/vomiting (89%) and dyspnea (80%). Esophagitis was absent (59% of patients) or mild (34% grade 1/2). At median follow-up of 9 months (range, 5-27 months), local control within the contoured target was 100%. One-year survival, disease-specific survival, and disease-free survival are 65%, 91%, and 88%, respectively.
Intensity-modulated radiotherapy after extrapleural pneumonectomy is tolerable and seems effective, at least at this early point. As local control improves, systemic metastases become more common, and it may be appropriate to add novel agents to further improve the therapeutic ratio.
尽管通过胸膜外全肺切除术和传统放疗进行了积极切除,但恶性胸膜间皮瘤仍常发生局部复发。这可能是由于未能识别临床靶区(CTV)的范围,或未能向紧邻心脏、食管、肝脏、肺、肾脏和脊髓的靶区提供最佳剂量。我们报告了在首例队列患者中如何通过利用调强放疗克服这些几何/剂量学限制。
28例行胸膜外全肺切除术的患者接受了调强放疗。CTV包括手术侵犯的内侧胸壁、膈肌附着处、胸膜反折和切口深部边缘。术中不透射线标记有助于CTV的勾画。评估了运动情况。CTV剂量为45 - 50 Gy,加量至60 Gy。
尽管CTV体积大且不规则(中位数为4151 cc;范围为2667 - 7286 cc),但平均97%的CTV被覆盖至靶剂量(范围为92% - 100%)。由于人工膈肌固定,呼吸运动极小。满足了正常组织剂量限制。最常见的不良反应是恶心/呕吐(89%)和呼吸困难(80%)。无食管炎(59%的患者)或轻度食管炎(34%为1/2级)。中位随访9个月(范围为5 - 27个月),勾画靶区内的局部控制率为100%。1年生存率、疾病特异性生存率和无病生存率分别为65%、91%和88%。
胸膜外全肺切除术后的调强放疗是可耐受的,且至少在早期似乎是有效的。随着局部控制的改善,全身转移变得更为常见,添加新型药物可能有助于进一步提高治疗比值。